ipharmacy

FDA Safety Alert

Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter

U.S. Food and Drug Administration
October 9, 2026
ID: http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-health-issues-voluntary-nationwide-recall-two-lots-brevitalr-sodium-500-mgvial-civ-methohexital

FDA MedWatch Safety Alert

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 8, 2026 –Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose.

Content syndicated from the official FDA MedWatch Safety Alerts and Adverse Event Reporting Program.

View Official Announcement on FDA.gov